NASDAQ:ACAD
ACADIA Pharmaceuticals Inc. Stock News
$16.82
-0.250 (-1.46%)
At Close: Apr 19, 2024
Pomerantz Law Firm Announces the Filing of a Class Action against Acadia Pharmaceuticals Inc. and Certain Officers - ACAD
11:24pm, Monday, 19'th Apr 2021
NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain o
San Francisco, California--(Newsfile Corp. - April 14, 2021) - Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is
San Francisco, California--(Newsfile Corp. - April 8, 2021) - Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is
After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers
05:36pm, Tuesday, 06'th Apr 2021
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares came under pressure Monday after the Food and Drug Administration (FDA) rejected its regulatory application seeking label expansion for its dementia
ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down
09:51am, Tuesday, 06'th Apr 2021
The FDA issues a Complete Response Letter to ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock falls.
ACADIA Pharmaceuticals Stock Price: $28 Target (Down From $50) By Morgan Stanley
07:55am, Tuesday, 06'th Apr 2021
The shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) have received a decreased price target from $50 to $28. These are the details.
Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc.
04:55am, Tuesday, 06'th Apr 2021
MILWAUKEE, April 6, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Acadia (NASDAQ: ACAD). The investigation results from inaccurate statements Acadia may ha
SAN FRANCISCO, April 5, 2021 /PRNewswire/ -- Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating po
Why Acadia Pharma, Bio-path And Cidara Are Moving Today
09:48am, Monday, 05'th Apr 2021
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and Cidara Therapeutics, Inc. (NASDAQ: CDTX) are among the early movers in the biotech space. ACADIA Wilts On FDA Rej
ACADIA Pharmaceuticals Stock Price Fell Over 19% Pre-Market: Why It Happened
08:46am, Monday, 05'th Apr 2021
The stock price of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) fell by over 19% pre-market. This is why it happened.
Acadia Stock Drops After FDA CRL For Pimavanserin Application In Hallucinations and Dementia-Related Psychosis
07:22am, Monday, 05'th Apr 2021
The FDA has issued a Complete Response Letter (CRL) to Acadia Pharmaceuticals Inc (NASDAQ: ACAD) regarding its supplemental marketing application (for Nuplazid (pimavanserin) for the treatment of
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) r
These 2 Scrappy Biotechs Could Skyrocket in April
06:11am, Sunday, 04'th Apr 2021
They've both taken a beating, but their fortunes may soon change.
Moving Average Crossover Alert: ACADIA Pharma
08:26am, Wednesday, 24'th Mar 2021
ACADIA Pharmaceuticals (ACAD) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
San Francisco, California--(Newsfile Corp. - March 15, 2021) - Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is
